Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

138
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
138
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

200
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
200
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

308
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
308
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

347
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
347
Renal Corpuscle01:20

Renal Corpuscle

5.5K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial.

Journal of the American Heart Association·2020
Same author

Funding kidney research as a public health priority: challenges and opportunities.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2020
Same author

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

The New England journal of medicine·2020
Same author

Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus.

Scientific reports·2020
Same author

Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.

International journal of molecular sciences·2020
Same author

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.

Diabetes, obesity & metabolism·2020
Same journal

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

["Not everything that looks like a tumor..." - Pulmonary tularemia with hilar lymphadenopathy].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Emergency management of sickle cell disease].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Hereditary dehydrated stomatocytosis (= hereditary xerocytosis) - Interesting hummingbird or clinically relevant diagnosis?]

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[Diagnosis of Congenital Hemolytic Anemias in Adults].

Deutsche medizinische Wochenschrift (1946)·2026
Same journal

[46-year-old female patient with right upper abdominal pain].

Deutsche medizinische Wochenschrift (1946)·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.5K

[Kidney as pacemaker for cardiovascular aging].

Christoph Wanner, Jan Galle, Kai Lopau

    Deutsche Medizinische Wochenschrift (1946)
    |March 1, 2021
    PubMed
    Summary
    This summary is machine-generated.

    Sodium-glucose cotransporter 2 (SGLT2) inhibitors protect kidneys and extend life for patients with type 2 diabetes and kidney disease. These drugs also benefit heart failure patients, with new multi-stage therapies showing complementary effects.

    More Related Videos

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
    07:52

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

    Published on: November 7, 2017

    21.4K
    Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
    11:53

    Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

    Published on: June 14, 2020

    7.9K

    Related Experiment Videos

    Last Updated: Nov 15, 2025

    Assessment of Vascular Function in Patients With Chronic Kidney Disease
    08:50

    Assessment of Vascular Function in Patients With Chronic Kidney Disease

    Published on: June 16, 2014

    16.5K
    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
    07:52

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

    Published on: November 7, 2017

    21.4K
    Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart
    11:53

    Simultaneous Isolation and Culture of Atrial Myocytes, Ventricular Myocytes, and Non-Myocytes from an Adult Mouse Heart

    Published on: June 14, 2020

    7.9K

    Area of Science:

    • Nephrology
    • Cardiology
    • Endocrinology

    Background:

    • Kidney disease accelerates aging and is exacerbated by vascular risk factors.
    • Type 2 diabetes mellitus combined with kidney disease can reduce lifespan by up to 16 years.
    • Sodium-glucose cotransporter 2 (SGLT2) inhibitors are crucial for maintaining kidney function.

    Purpose of the Study:

    • To explore the role of SGLT2 inhibitors in promoting longevity in kidney patients.
    • To discuss the benefits of SGLT2 inhibitors in patients with type 2 diabetes and kidney disease.
    • To introduce a novel 3-stage therapy for heart failure incorporating SGLT2 inhibitors.

    Main Methods:

    • Inhibition of the SGLT2 transporter in the kidney's proximal tubule.
    • Induction of a hypometabolic state through continuous excretion of energy and water.
    • Combination therapy involving beta blockers, SGLT2 inhibitors, angiotensin receptor/neprilysin inhibitors, and mineralocorticoid receptor antagonists.

    Main Results:

    • SGLT2 inhibition supports organ function and promotes longevity.
    • Kidney protection via SGLT2 inhibitors extends life expectancy in type 2 diabetes patients.
    • A multi-stage therapeutic approach for heart failure demonstrates complementary effects.

    Conclusions:

    • SGLT2 inhibitors offer significant benefits for kidney health and longevity, particularly in patients with type 2 diabetes.
    • The use of SGLT2 inhibitors is expanding to include heart failure management.
    • A sequential combination therapy involving SGLT2 inhibitors shows promise for comprehensive cardiovascular and renal protection.